Bard gets exclusive endoluminal graft rights:
This article was originally published in Clinica
CR Bard has signed an exclusive agreement to distribute the CE-marked Endoluminal graft from Endologix in Europe and Australia. Endologix has initiated Japanese clinical studies and plans to start a US FDA Phase I IDE study in September. Bard, which has an option to buy the entire Irvine, California-based company before the end of 2000, says that the graft has demonstrated low endoleak rates and ease of delivery.